PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “PULMONARY HEART DISEASE”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 181 records · Page 10Linked to original sources
PubMed1996

[An new index to evaluate the elderly health care-geracomia effect index].

This paper introduced a new index--geracomia effect index (GEI) which is expressed by the ratio of survival years of the elderly after their retirement to the expected survival years in order to evaluate the health care service to the elderly. The application of this index was discussed using the mortality data of cardiovascular diseases of a city from 1983 to 1994. The results showed that coronary heart disease, pulmonary heart disease and cerebrovascular disease had a stable influence on the survival years of the elderly during this period while the negative effect of diabetes had been weaken with the calendar years. However, myocardial infarction had begun to threaten the younger groups. The author realized that it needs further practice to make the index applicable.

Aged↗
PubMed1996

[The trend of changes in etiologic types of heart diseases in Shanghai from 1948 to 1989].

Analysis of the data from 7188 cases seen in the 1980s two general hospitals in Shanghai and comparison of the data with those in the 1950s, 1960s and 1970s revealed that the percentage of heart diseases among the inpatients in medical wards increased in each decades, from 9.89%, 15.69% 20.91% to 23.54% respectively. The constituent ratios of different etiologic types of heart diseases changed. Coronary heart disease constituted the largest proportion, next in number was rheumatic heart disease and congenital heart disease was in the third place. The incidence of congenital heart diseases, myocarditis, cardiac dysrhythmias without organic heart diseases, cardiomyopathy and endocarditis increased and that of rheumatic heart disease, pulmonary heart disease and hypertensive heart disease apparently decreased, syphilitic heart disease was rarely encountered.

Adolescent↗
PubMed1998

[Chronic pulmonary heart diseases treated by fraxiparin].

OBJECTIVE: The effects of fraxiparine with hypodermic on the treatment of patients with chronic pulmonary heart diseases(CPHD) at acute phase were studied. METHODS: Twenty patients were hypodermically injected with 0.4 ml fraxiparine per day for 7 days as a course. Fibrin fibrinogen degradation products (FDP and D-dimer), antithrombin III (AT-III), PaO2 and PaCO2 were detected before and after the treatment. RESULTS: In the therapy group, FDP and D-dimer decreased after the treatment, AT-III increased. All indexes didn't alter in the control group. CONCLUSION: Fraxiparine is effective on patients with CPHD at acute phase.

Adult↗
PubMed1996

[Deaths from asthma, bronchitis and pulmonary heart disease in Warsaw in the years 1993-1994].

By the regular checking the death certificates in the municipal offices in 7 districts of Warsaw, the morality rate from asthma has been established as 2.98/100.000, from chronic bronchitis as 8.71/100.000 and from pulmonary heart disease as 6.27/100.000. During one year of this survey only 15 deaths (4.7%) from these diseases were below age of 50.67% of patients died in hospitals and 22 (7%) died suddenly (at home). In general, deaths reported as the results of COLD were only 1.59% of the total number of deaths in Warsaw (21.530). 6.9% of all death certificates were without clinical diagnosis (Number 798 of ICD)-described as "natural death", "death before doctor's arrival" or "noncriminal death". Authors discuss the problem of over- and under-diagnosis of asthma as the cause of death, the historical background of asthma mortality and also put the question of the righteousness of regard the pulmonary heart disease as the primary cause of death.

Aged↗
PubMed2002

[Pathogen variance and drug-sensibility analysis of lower-respiratory-tract bacterial infection in chronic pulmonary heart disease].

We contrastively analyzed pathogens and their drug sensibilities of lower-respiratory-tract infection in chronic pulmonary heart disease in two different periods. The results were that the Gram-positive cocci (GPC) was 43.8% and Gram-negative bacilli (GNB) was 56.2% in Group A (1985-1990); GPC was 24.6% and GNB was 75.4% in Group B (1995-2000). The predominant bacteria were in the following order: Preudomonas (21.9%), pneumococcal (18.8%), streptococcus (10.9%), acinetobacter (9.4%), staphylococcus epidermidis (7.8%), and klebsiella (7.8%) in Group A; and preudomonas (30.7%), acinetobacter (12.3%), staphylococcus epidermidis (12.3%), klebsiella (10.5%), enteric bacilli (7.0%), and staphylococcus aureus (7.0%) in Group B. The results suggest that GNB is the main pathogen in recent years; sensibility of most drugs in the 1990s fell in varying degrees compared with that in the 1980s, but antibacterial in common use is still available.

Adult↗
PubMed2006

[Clinical observation on shufei granule in improving right ventricular function of patients with chronic pulmonary heart disease].

OBJECTIVE: To observe the effect of Shufei Granule (SG) on right ventricular function in patients with chronic pulmonary heart disease (CPHD). METHODS: One hundred CPHD patients were randomly divided into two groups, the control group (n = 40) treated with fleroxacin 0.2 g twice per day by intravenous dripping and diprophylline 0.2 g 3 times per day orally, the treatment group (n = 60) treated with SG 10 g 3 times a day orally additionally besides the treatment given to the control group. The therapeutic course for both groups was 3 weeks. The changes of the cardiac function, the right ventricular function [A peak velocity (VA), E peak velocity (VE), VA/VE, systolic pulmonary artery pressure (SPAP), pre-ejection period (PEP), right ventricular ejection time (RVET), PEP/RVET], and blood-gas analysis were investigated, the condition of clinical symptoms and signs as well as tongue pictures were observed also. RESULTS: The total effective rate was 91.6% in the treated group, significantly higher than that in the control group (70.0%, P < 0.01); the improvements in symptom score, cardiac function and the other laboratory indexes were all superior in the treatment group to those in the control group (P < 0.05, P < 0.01). CONCLUSION: SG is an effective drug for improving right ventricular function in CPHD patients.

Adult↗
PubMed2003

[Changes of NO and ET-1 in the blood of patients with chronic pulmonary heart disease].

OBJECTIVE: To study the changes of nitric oxide (NO), and endothelin-1 (ET-1) in patients with chronic pulmonary heart disease (CPHD), and to understand its pathophysiology, observe its severity, assess its prognosis and find clues to some new management methods. METHODS: Forty-five patients with CPHD at the acute exacerbation stage, 20 patients with CPHD at the stable stage and 18 healthy controls were studied. The NO and ET-1 levels were measured by spectrophotometry and radioimmunoassay respectively. RESULTS: 1. The ratio of ET-1/NO in the patients with CPHD at the acute exacerbation stage was higher than that in the patients at the stable stage (P < 0.05), and heathily controls (P < 0.05), the ratio of ET-1/NO in the patients with CPHD at the stable stage was higher than that in the control group (P < 0.05); 2. The NO level in the patients with CPHD at the acute exacerbation stage or stable stage was positively related with PO2(r = 0.85, P < 0.05, r = 0.72, P < 0.05), but negatively related with PCO2(r = -0.54, P < 0.05, r = -0.52, P < 0.05); the ET-1 level in the patients with CPHD at the acute exacerbation stage or stable stage was negatively related with PO2(r = -0.72, P < 0.05, r = -0.53, P < 0.05), but positively related with PCO2(r = 0.55, P < 0.05, r = 0.53, P < 0.05); 3. The serial changes of NO and ET-1 also demonstrated these correlations; 4. The NO level was elevated in those patients with better symptomatic improvement following management (P < 0.05), while the ET-1 level and the ratio of ET-1/NO decreased significantly in the patients with symptomatic improvement (P < 0.05), and there was no significant change in the patients with no symptomatic improvement following management or in the dead patients(P > 0.05). CONCLUSION: The imbalance between ET-1 and NO exists in patients with CPHD, and it is closely associated with hypoxia and may play an important role in the occurrence and development of pulmonary hypertension and CPHD. NO and ET-1 can serve as indicators to observe the disease severity and assess its prognosis.

Aged↗
PubMed1988

[Chronic respiratory insufficiency and pulmonary heart disease--therapeutic aspects].

The term chronic respiratory insufficiency embraces always the involvement of the heart under the picture of pulmonary heart disease. The pathogenetic peculiarities of the impairment of the heart function and of the development of oedemas must be considered in the treatment. At present, treatment can only be symptomatic, and its long-term efficiency must be critically estimated. The importance of long-term oxygen therapy at home is explained.

Combined Modality Therapy↗